Study on the diagnostic criteria of syndrome of dampness obstruction in idiopathic membranous nephropathy based on expert consensus. [PDF]
Dan W +7 more
europepmc +1 more source
Screening potential diagnostic biomarkers for PLA2R‑associated idiopathic membranous nephropathy by WGCNA analysis and LASSO algorithm. [PDF]
Huang J +6 more
europepmc +1 more source
Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy. [PDF]
Li Z +8 more
europepmc +1 more source
Clinical study, network pharmacology, and molecular docking of Kunxian capsule in treating idiopathic membranous nephropathy. [PDF]
Lv J, Gao X, Liu L, He L, Tian G, Lu X.
europepmc +1 more source
Effect of QingreHuoxue formula on Th17 cells and Tregs in mice with idiopathic membranous nephropathy. [PDF]
Lou C +9 more
europepmc +1 more source
Clinicopathological and prognostic study of idiopathic membranous nephropathy with tip or non-tip variant focal segmental glomerulosclerosis: a single-center cohort study. [PDF]
Xu S +8 more
europepmc +1 more source
B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China. [PDF]
Xu Y +28 more
europepmc +1 more source
Prognostic value of serum complement cleavage factor Bb in idiopathic membranous nephropathy and establishment of nomogram model. [PDF]
Wen L, Li Q, Cheng G, Zhang Y, Zhao Z.
europepmc +1 more source
Efficacy of sulodexide in treating idiopathic membranous nephropathy among Chinese patients: a meta-analysis. [PDF]
Wang T +7 more
europepmc +1 more source
Rituximab for Idiopathic Membranous Nephropathy
Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m(2)-- the monoclonal antibody to B-cell antigen CD20--in eight patients who had idiopathic membranous nephropathy
Giuseppe Remuzzi +2 more
exaly +4 more sources

